stockrow
Saturday 7 November 2026
Export NKTX’s income statement to Excel — free account
Nkarta, Inc.
NKTX Healthcare Biotechnology
- EPS
- −74.2%
- Free cash flow
- −29.2%
Quarter to June 2026, against a year earlier
1.75
0.18
+11.46%
Follow NKTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 7 | 0 | — | — | — | — | — | — | — | (98.2%) | 3 | 3 | 3 | 0.0% | |
| Gross margin, % | — | — | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | 0 | (21) | (91) | (86) | (114) | (118) | (109) | (104) | (117) | +133.6% | ||||||
| EBT margin, % | — | — | (4.19) | (18,326.96) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +4.2 pt | ||||||
| Net income | — | 0 | 0 | (21) | (91) | (86) | (114) | (118) | (109) | (104) | (117) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.20 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.01) | (14.41) | (5.44) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) | (1.57) | +102.8% | ||||||
| Cash flow | — | — | (0.16) | (12.55) | (2.59) | (2.07) | (1.31) | (1.76) | (1.47) | (1.20) | (1.25) | +33.4% | ||||||
| Capex | — | — | 0.00 | (1.32) | (0.45) | (0.15) | (1.08) | (0.57) | (0.06) | (0.02) | (0.02) | n/m | ||||||
| Free cash flow | — | — | (0.16) | (13.87) | (3.04) | (2.22) | (2.39) | (2.33) | (1.53) | (1.22) | (1.26) | +33.7% | ||||||
| Book value | — | — | (0.17) | (17.42) | 19.11 | 7.64 | 8.53 | 5.58 | 6.01 | 4.22 | 3.33 | n/m | ||||||
| Shares, m | — | — | 33 | 1 | 17 | 33 | 44 | 49 | 68 | 74 | 74 | +12.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | ||||||
| P/B | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 0.53 | 0.0 | ||||||
| EV/Sales | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | (1.67) | (1.67) | — | — | — | — | — | — | 0.56 | (1.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (5) | (18) | (44) | (68) | (57) | (86) | (100) | (89) | (93) | +50.0% | |||||
| Capex | — | — | (1) | (2) | (8) | (5) | (47) | (28) | (4) | (1) | (1) | +6.9% | ||||||
| Free cash flow | — | — | (5) | (20) | (51) | (73) | (104) | (114) | (104) | (90) | (94) | +50.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 6 | 29 | 310 | 233 | 339 | 230 | 254 | 260 | 164 | +70.7% | |||||
| Net debt | — | — | 5 | (37) | (315) | (238) | (352) | (248) | (267) | (276) | (183) | n/m | ||||||
| Shareholders’ equity | — | — | (5) | (25) | 321 | 251 | 372 | 273 | 408 | 312 | 248 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (5.72) | (72.65) | (47.33) | (28.15) | (30.48) | (27.59) | (24.72) | (22.99) | (29.86) | (17.3) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | (510.42) | (419.43) | (370.55) | (327.87) | (56.98) | (211.53) | (127.22) | (211.5) pt | ||||||
| ROE | — | — | 1.78 | 136.51 | (61.79) | (30.09) | (36.53) | (36.41) | (31.94) | (28.90) | (38.76) | (30.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 70 | 95 | 136 | 163 | 150 | 157 | 108 | — | +7.5% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2019 · latest quarter Jun 2019
Nkarta, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CHRS Coherus Oncology, Inc. | $115.7M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| PYPD PolyPid Ltd. | $115.2M | — (loss-making) | — | — | n/m | −64.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FHTX Foghorn Therapeutics Inc. | $113.1M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| ENGN enGene Therapeutics Inc | $112.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| NKTX Nkarta, Inc. | $112.5M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | |
| CDXS Codexis, Inc. | $111.7M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $111.5M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| HUMA Humacyte, Inc. | $109.9M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | Compare |
| NERV Minerva Neurosciences, Inc | $109.8M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $112.1M | — | — | +34.88% | — | −1.55% | 70.35% | (65.03%) |
Pay and ownership Proxy statement filed 23 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.98m | 2.04m | 28.03 |
| 2024 | 3.99m | 1.54m | 37.73 |
Ownership
Directors and executive officers, together
9.80%
Entities affiliated with RA Capital
18.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement